You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIfenprodil
Accession NumberDB08954
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionIfenprodil is a selective NMDA receptor (glutamate) antagonist.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • RC 61-91
  • RC 61-96
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CerocralSanofi
FurezanilTsuruhara Seiyaku
IburonolTowa Yakuhin
LinbulaneTatsumi Kagaku
TechnisSawai Seiyaku
VadilexSanofi
VasculodilKyowa Yakuhin
YouajylYoshindo
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ifenprodil Tartrate
ThumbNot applicableDBSALT001078
Categories
UNIIR8OE3P6O5S
CAS number23210-56-2
WeightAverage: 325.4446
Monoisotopic: 325.204179113
Chemical FormulaC21H27NO2
InChI KeyInChIKey=UYNVMODNBIQBMV-UHFFFAOYNA-N
InChI
InChI=1/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
IUPAC Name
4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
SMILES
CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP3.98ALOGPS
logP3.57ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)9.67ChemAxon
pKa (Strongest Basic)9.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity98.35 m3·mol-1ChemAxon
Polarizability37.52 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,509,164.

General ReferencesNot Available
External Links
ATC CodesC04AX28
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabIfenprodil may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of Ifenprodil.
AcenocoumarolIfenprodil may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Ifenprodil.
AlprostadilAlprostadil may increase the antiplatelet activities of Ifenprodil.
AlteplaseIfenprodil may increase the anticoagulant activities of Alteplase.
ALX-0081Ifenprodil may increase the anticoagulant activities of ALX-0081.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Aminosalicylic Acid.
AnagrelideIfenprodil may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of Ifenprodil.
AncrodIfenprodil may increase the anticoagulant activities of Ancrod.
AnistreplaseIfenprodil may increase the anticoagulant activities of Anistreplase.
Antithrombin III humanIfenprodil may increase the anticoagulant activities of Antithrombin III human.
ApixabanIfenprodil may increase the anticoagulant activities of Apixaban.
ArdeparinIfenprodil may increase the anticoagulant activities of Ardeparin.
ArgatrobanIfenprodil may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of Ifenprodil.
AstaxanthinIfenprodil may increase the anticoagulant activities of Astaxanthin.
AzelastineAzelastine may increase the antiplatelet activities of Ifenprodil.
BatroxobinIfenprodil may increase the anticoagulant activities of Batroxobin.
BecaplerminIfenprodil may increase the anticoagulant activities of Becaplermin.
BemiparinIfenprodil may increase the anticoagulant activities of Bemiparin.
BeraprostIfenprodil may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of Ifenprodil.
BivalirudinIfenprodil may increase the anticoagulant activities of Bivalirudin.
CangrelorIfenprodil may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of Ifenprodil.
CertoparinIfenprodil may increase the anticoagulant activities of Certoparin.
CilostazolIfenprodil may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of Ifenprodil.
Citric AcidIfenprodil may increase the anticoagulant activities of Citric Acid.
ClopidogrelIfenprodil may increase the anticoagulant activities of Clopidogrel.
ClopidogrelClopidogrel may increase the antiplatelet activities of Ifenprodil.
CollagenaseThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Collagenase.
Dabigatran etexilateIfenprodil may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinIfenprodil may increase the anticoagulant activities of Dalteparin.
DanaparoidIfenprodil may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of Ifenprodil.
DefibrotideIfenprodil may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of Ifenprodil.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Deoxycholic Acid.
DesirudinIfenprodil may increase the anticoagulant activities of Desirudin.
DesmoteplaseIfenprodil may increase the anticoagulant activities of Desmoteplase.
DextranIfenprodil may increase the anticoagulant activities of Dextran.
Dextran 40Ifenprodil may increase the anticoagulant activities of Dextran 40.
Dextran 70Ifenprodil may increase the anticoagulant activities of Dextran 70.
Dextran 75Ifenprodil may increase the anticoagulant activities of Dextran 75.
DicoumarolIfenprodil may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Diflunisal.
DipyridamoleIfenprodil may increase the anticoagulant activities of Dipyridamole.
DipyridamoleDipyridamole may increase the antiplatelet activities of Ifenprodil.
DitazoleIfenprodil may increase the anticoagulant activities of Ditazole.
Drotrecogin alfaIfenprodil may increase the anticoagulant activities of Drotrecogin alfa.
Edetic AcidIfenprodil may increase the anticoagulant activities of Edetic Acid.
EdoxabanIfenprodil may increase the anticoagulant activities of Edoxaban.
EnoxaparinIfenprodil may increase the anticoagulant activities of Enoxaparin.
EpinastineEpinastine may increase the antiplatelet activities of Ifenprodil.
EpoprostenolIfenprodil may increase the anticoagulant activities of Epoprostenol.
EpoprostenolEpoprostenol may increase the antiplatelet activities of Ifenprodil.
EptifibatideIfenprodil may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of Ifenprodil.
Ethyl biscoumacetateIfenprodil may increase the anticoagulant activities of Ethyl biscoumacetate.
FibrinolysinIfenprodil may increase the anticoagulant activities of Fibrinolysin.
Fondaparinux sodiumIfenprodil may increase the anticoagulant activities of Fondaparinux sodium.
GlucosamineGlucosamine may increase the antiplatelet activities of Ifenprodil.
HeparinIfenprodil may increase the anticoagulant activities of Heparin.
HirulogIfenprodil may increase the anticoagulant activities of Hirulog.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ifenprodil.
IbudilastIbudilast may increase the antiplatelet activities of Ifenprodil.
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Ifenprodil.
IloprostIfenprodil may increase the anticoagulant activities of Iloprost.
IloprostIloprost may increase the antiplatelet activities of Ifenprodil.
LepirudinIfenprodil may increase the anticoagulant activities of Lepirudin.
LimaprostLimaprost may increase the antiplatelet activities of Ifenprodil.
MefloquineThe therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mefloquine.
MesalazineThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Mesalazine.
MianserinThe therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mianserin.
MilrinoneMilrinone may increase the antiplatelet activities of Ifenprodil.
NadroparinIfenprodil may increase the anticoagulant activities of Nadroparin.
NCX 4016Ifenprodil may increase the anticoagulant activities of NCX 4016.
NCX 4016NCX 4016 may increase the antiplatelet activities of Ifenprodil.
NimesulideNimesulide may increase the antiplatelet activities of Ifenprodil.
ObinutuzumabThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ifenprodil.
OrlistatThe serum concentration of Ifenprodil can be decreased when it is combined with Orlistat.
OtamixabanIfenprodil may increase the anticoagulant activities of Otamixaban.
ParnaparinIfenprodil may increase the anticoagulant activities of Parnaparin.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ifenprodil.
Pentosan PolysulfateIfenprodil may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Ifenprodil.
PhenindioneIfenprodil may increase the anticoagulant activities of Phenindione.
PhenprocoumonIfenprodil may increase the anticoagulant activities of Phenprocoumon.
PlasminIfenprodil may increase the anticoagulant activities of Plasmin.
PrasugrelIfenprodil may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of Ifenprodil.
Protein CIfenprodil may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeIfenprodil may increase the anticoagulant activities of Protocatechualdehyde.
ResveratrolResveratrol may increase the antiplatelet activities of Ifenprodil.
ReteplaseIfenprodil may increase the anticoagulant activities of Reteplase.
ReviparinIfenprodil may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the antiplatelet activities of Ifenprodil.
RivaroxabanIfenprodil may increase the anticoagulant activities of Rivaroxaban.
RosiglitazoneIfenprodil may increase the anticoagulant activities of Rosiglitazone.
Salicylic acidThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Salicylic acid.
SCH-530348SCH-530348 may increase the antiplatelet activities of Ifenprodil.
SelexipagIfenprodil may increase the anticoagulant activities of Selexipag.
SevofluraneSevoflurane may increase the antiplatelet activities of Ifenprodil.
SRT501SRT501 may increase the antiplatelet activities of Ifenprodil.
StreptokinaseIfenprodil may increase the anticoagulant activities of Streptokinase.
SulodexideIfenprodil may increase the anticoagulant activities of Sulodexide.
TenecteplaseIfenprodil may increase the anticoagulant activities of Tenecteplase.
TesmilifeneTesmilifene may increase the antiplatelet activities of Ifenprodil.
TicagrelorIfenprodil may increase the anticoagulant activities of Ticagrelor.
TiclopidineIfenprodil may increase the anticoagulant activities of Ticlopidine.
TiclopidineTiclopidine may increase the antiplatelet activities of Ifenprodil.
TinzaparinIfenprodil may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Ifenprodil.
TirofibanIfenprodil may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of Ifenprodil.
TositumomabThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Tositumomab.
TranilastTranilast may increase the antiplatelet activities of Ifenprodil.
TrapidilIfenprodil may increase the antiplatelet activities of Trapidil.
TreprostinilIfenprodil may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of Ifenprodil.
TriflusalIfenprodil may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of Ifenprodil.
UrokinaseIfenprodil may increase the anticoagulant activities of Urokinase.
Vitamin EVitamin E may increase the antiplatelet activities of Ifenprodil.
VorapaxarIfenprodil may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of Ifenprodil.
WarfarinIfenprodil may increase the anticoagulant activities of Warfarin.
XimelagatranIfenprodil may increase the anticoagulant activities of Ximelagatran.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (...
Gene Name:
GRIN1
Uniprot ID:
Q05586
Molecular Weight:
105371.945 Da
References
  1. Seppala T, Stromberg C, Mattila MJ: Effects of the novel 5-hydroxytryptamine reuptake inhibitor indalpine and ethanol on psychomotor performance. Arzneimittelforschung. 1988 Jan;38(1):98-102. [PubMed:3365283 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an ...
Gene Name:
GRIN2B
Uniprot ID:
Q13224
Molecular Weight:
166365.885 Da
References
  1. Seppala T, Stromberg C, Mattila MJ: Effects of the novel 5-hydroxytryptamine reuptake inhibitor indalpine and ethanol on psychomotor performance. Arzneimittelforschung. 1988 Jan;38(1):98-102. [PubMed:3365283 ]
Comments
comments powered by Disqus
Drug created on May 28, 2014 11:48 / Updated on August 17, 2016 12:24